Report Detail

Pharma & Healthcare Global Transthyretin Stabilizer Market Research Report 2022

  • RnM4438734
  • |
  • 11 May, 2022
  • |
  • Global
  • |
  • 98 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Transthyretin Stabilizer Market Overview

    • 1.1 Product Overview and Scope of Transthyretin Stabilizer
    • 1.2 Transthyretin Stabilizer Segment by Type
      • 1.2.1 Global Transthyretin Stabilizer Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Diflunisal
      • 1.2.3 Tafamidis
      • 1.2.4 Others
    • 1.3 Transthyretin Stabilizer Segment by Application
      • 1.3.1 Global Transthyretin Stabilizer Sales Comparison by Application: (2022-2028)
      • 1.3.2 Hospital Pharmacies
      • 1.3.3 Retail Pharmacies
      • 1.3.4 Drug Stores
      • 1.3.5 Online Pharmacies
      • 1.3.6 Others
    • 1.4 Global Transthyretin Stabilizer Market Size Estimates and Forecasts
      • 1.4.1 Global Transthyretin Stabilizer Revenue 2017-2028
      • 1.4.2 Global Transthyretin Stabilizer Sales 2017-2028
      • 1.4.3 Transthyretin Stabilizer Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Transthyretin Stabilizer Market Competition by Manufacturers

    • 2.1 Global Transthyretin Stabilizer Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Transthyretin Stabilizer Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Transthyretin Stabilizer Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Transthyretin Stabilizer Manufacturing Sites, Area Served, Product Type
    • 2.5 Transthyretin Stabilizer Market Competitive Situation and Trends
      • 2.5.1 Transthyretin Stabilizer Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Transthyretin Stabilizer Players Market Share by Revenue
      • 2.5.3 Global Transthyretin Stabilizer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Transthyretin Stabilizer Retrospective Market Scenario by Region

    • 3.1 Global Transthyretin Stabilizer Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Transthyretin Stabilizer Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Transthyretin Stabilizer Market Facts & Figures by Country
      • 3.3.1 North America Transthyretin Stabilizer Sales by Country
      • 3.3.2 North America Transthyretin Stabilizer Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Transthyretin Stabilizer Market Facts & Figures by Country
      • 3.4.1 Europe Transthyretin Stabilizer Sales by Country
      • 3.4.2 Europe Transthyretin Stabilizer Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Transthyretin Stabilizer Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Transthyretin Stabilizer Sales by Region
      • 3.5.2 Asia Pacific Transthyretin Stabilizer Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Transthyretin Stabilizer Market Facts & Figures by Country
      • 3.6.1 Latin America Transthyretin Stabilizer Sales by Country
      • 3.6.2 Latin America Transthyretin Stabilizer Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
    • 3.7 Middle East and Africa Transthyretin Stabilizer Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Transthyretin Stabilizer Sales by Country
      • 3.7.2 Middle East and Africa Transthyretin Stabilizer Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Transthyretin Stabilizer Historic Market Analysis by Type

    • 4.1 Global Transthyretin Stabilizer Sales Market Share by Type (2017-2022)
    • 4.2 Global Transthyretin Stabilizer Revenue Market Share by Type (2017-2022)
    • 4.3 Global Transthyretin Stabilizer Price by Type (2017-2022)

    5 Global Transthyretin Stabilizer Historic Market Analysis by Application

    • 5.1 Global Transthyretin Stabilizer Sales Market Share by Application (2017-2022)
    • 5.2 Global Transthyretin Stabilizer Revenue Market Share by Application (2017-2022)
    • 5.3 Global Transthyretin Stabilizer Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Pfizer Inc.
      • 6.1.1 Pfizer Inc. Corporation Information
      • 6.1.2 Pfizer Inc. Description and Business Overview
      • 6.1.3 Pfizer Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Pfizer Inc. Transthyretin Stabilizer Product Portfolio
      • 6.1.5 Pfizer Inc. Recent Developments/Updates
    • 6.2 Merck & Co.
      • 6.2.1 Merck & Co. Corporation Information
      • 6.2.2 Merck & Co. Description and Business Overview
      • 6.2.3 Merck & Co. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Merck & Co. Transthyretin Stabilizer Product Portfolio
      • 6.2.5 Merck & Co. Recent Developments/Updates
    • 6.3 AstraZeneca Plc.
      • 6.3.1 AstraZeneca Plc. Corporation Information
      • 6.3.2 AstraZeneca Plc. Description and Business Overview
      • 6.3.3 AstraZeneca Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 AstraZeneca Plc. Transthyretin Stabilizer Product Portfolio
      • 6.3.5 AstraZeneca Plc. Recent Developments/Updates
    • 6.4 GlaxoSmithKline Plc.
      • 6.4.1 GlaxoSmithKline Plc. Corporation Information
      • 6.4.2 GlaxoSmithKline Plc. Description and Business Overview
      • 6.4.3 GlaxoSmithKline Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 GlaxoSmithKline Plc. Transthyretin Stabilizer Product Portfolio
      • 6.4.5 GlaxoSmithKline Plc. Recent Developments/Updates
    • 6.5 Corino Therapeutics Inc.
      • 6.5.1 Corino Therapeutics Inc. Corporation Information
      • 6.5.2 Corino Therapeutics Inc. Description and Business Overview
      • 6.5.3 Corino Therapeutics Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Corino Therapeutics Inc. Transthyretin Stabilizer Product Portfolio
      • 6.5.5 Corino Therapeutics Inc. Recent Developments/Updates
    • 6.6 Alnylam Pharmaceuticals
      • 6.6.1 Alnylam Pharmaceuticals Corporation Information
      • 6.6.2 Alnylam Pharmaceuticals Description and Business Overview
      • 6.6.3 Alnylam Pharmaceuticals Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Alnylam Pharmaceuticals Transthyretin Stabilizer Product Portfolio
      • 6.6.5 Alnylam Pharmaceuticals Recent Developments/Updates
    • 6.7 Bellus Health Inc.
      • 6.6.1 Bellus Health Inc. Corporation Information
      • 6.6.2 Bellus Health Inc. Description and Business Overview
      • 6.6.3 Bellus Health Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Bellus Health Inc. Transthyretin Stabilizer Product Portfolio
      • 6.7.5 Bellus Health Inc. Recent Developments/Updates
    • 6.8 Ionis Pharmaceuticals, Inc.
      • 6.8.1 Ionis Pharmaceuticals, Inc. Corporation Information
      • 6.8.2 Ionis Pharmaceuticals, Inc. Description and Business Overview
      • 6.8.3 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Ionis Pharmaceuticals, Inc. Transthyretin Stabilizer Product Portfolio
      • 6.8.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
    • 6.9 Proclara Bioscience
      • 6.9.1 Proclara Bioscience Corporation Information
      • 6.9.2 Proclara Bioscience Description and Business Overview
      • 6.9.3 Proclara Bioscience Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 Proclara Bioscience Transthyretin Stabilizer Product Portfolio
      • 6.9.5 Proclara Bioscience Recent Developments/Updates
    • 6.10 Arturus Therapeutics
      • 6.10.1 Arturus Therapeutics Corporation Information
      • 6.10.2 Arturus Therapeutics Description and Business Overview
      • 6.10.3 Arturus Therapeutics Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Arturus Therapeutics Transthyretin Stabilizer Product Portfolio
      • 6.10.5 Arturus Therapeutics Recent Developments/Updates
    • 6.11 Prothena Corporation Plc.
      • 6.11.1 Prothena Corporation Plc. Corporation Information
      • 6.11.2 Prothena Corporation Plc. Transthyretin Stabilizer Description and Business Overview
      • 6.11.3 Prothena Corporation Plc. Transthyretin Stabilizer Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Prothena Corporation Plc. Transthyretin Stabilizer Product Portfolio
      • 6.11.5 Prothena Corporation Plc. Recent Developments/Updates

    7 Transthyretin Stabilizer Manufacturing Cost Analysis

    • 7.1 Transthyretin Stabilizer Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Transthyretin Stabilizer
    • 7.4 Transthyretin Stabilizer Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Transthyretin Stabilizer Distributors List
    • 8.3 Transthyretin Stabilizer Customers

    9 Transthyretin Stabilizer Market Dynamics

    • 9.1 Transthyretin Stabilizer Industry Trends
    • 9.2 Transthyretin Stabilizer Market Drivers
    • 9.3 Transthyretin Stabilizer Market Challenges
    • 9.4 Transthyretin Stabilizer Market Restraints

    10 Global Market Forecast

    • 10.1 Transthyretin Stabilizer Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Transthyretin Stabilizer by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Transthyretin Stabilizer by Type (2023-2028)
    • 10.2 Transthyretin Stabilizer Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Transthyretin Stabilizer by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Transthyretin Stabilizer by Application (2023-2028)
    • 10.3 Transthyretin Stabilizer Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Transthyretin Stabilizer by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Transthyretin Stabilizer by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:

      Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.
      Industry Insights
      Due to the COVID-19 pandemic, the global Transthyretin Stabilizer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Transthyretin Stabilizer market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Transthyretin Stabilizer landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
      Diflunisal accounting for % of the Transthyretin Stabilizer global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
      The global major manufacturers of Transthyretin Stabilizer include Pfizer Inc., Merck & Co., AstraZeneca Plc., GlaxoSmithKline Plc., Corino Therapeutics Inc., Alnylam Pharmaceuticals, Bellus Health Inc., Ionis Pharmaceuticals, Inc. and Proclara Bioscience, etc. In terms of revenue, the global 3 largest players have a % market share of Transthyretin Stabilizer in 2021.
      This report focuses on Transthyretin Stabilizer volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Transthyretin Stabilizer market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
      Key Drivers & Barriers
      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
      Post-covid-19 Outlook
      The readers in the section will understand how the Transthyretin Stabilizer market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
      Segmental Outlook
      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
      Segment by Type
      Diflunisal
      Tafamidis
      Others
      Segment by Application
      Hospital Pharmacies
      Retail Pharmacies
      Drug Stores
      Online Pharmacies
      Others
      Regional Outlook
      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Scenario
      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
      Pfizer Inc.
      Merck & Co.
      AstraZeneca Plc.
      GlaxoSmithKline Plc.
      Corino Therapeutics Inc.
      Alnylam Pharmaceuticals
      Bellus Health Inc.
      Ionis Pharmaceuticals, Inc.
      Proclara Bioscience
      Arturus Therapeutics
      Prothena Corporation Plc.
      Frequently Asked Questions
      Which product segment grabbed the largest share in the Transthyretin Stabilizer market?
      How is the competitive scenario of the Transthyretin Stabilizer market?
      Which are the key factors aiding the Transthyretin Stabilizer market growth?
      Which are the prominent players in the Transthyretin Stabilizer market?
      Which region holds the maximum share in the Transthyretin Stabilizer market?
      What will be the CAGR of the Transthyretin Stabilizer market during the forecast period?
      Which application segment emerged as the leading segment in the Transthyretin Stabilizer market?
      What key trends are likely to emerge in the Transthyretin Stabilizer market in the coming years?
      What will be the Transthyretin Stabilizer market size by 2028?
      Which company held the largest share in the Transthyretin Stabilizer market?


      Summary:
      Get latest Market Research Reports on Transthyretin Stabilizer. Industry analysis & Market Report on Transthyretin Stabilizer is a syndicated market report, published as Global Transthyretin Stabilizer Market Research Report 2022. It is complete Research Study and Industry Analysis of Transthyretin Stabilizer market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,308.40
      4,616.80
      2,720.20
      5,440.40
      370,359.00
      740,718.00
      224,663.00
      449,326.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report